Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
63,343,880
-
Share change
-
-1,172,885
-
Total reported value
-
$56,369,746
-
Price per share
-
$0.89
-
Number of holders
-
86
-
Value change
-
-$1,146,000
-
Number of buys
-
36
-
Number of sells
-
25
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q4 2019
As of 31 Dec 2019,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,343,880 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock Inc., VANGUARD GROUP INC, Defender Capital, LLC., Prescott General Partners LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, BRIDGEWAY CAPITAL MANAGEMENT INC, and Northeast Financial Consultants Inc.
This page lists
86
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.